News and Announcements
Kinesis Monetary System CEO believes technology is the key to reconstructing trust in the financial services sector
- Published September 19, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- CEO of Kinesis Monetary System, Thomas Coughlin, believes technology can rebuild trust in the financial services sector.
- Ten years on from the credit crisis, blockchain may be the key to rebuilding trust.
- Mr Coughlin believes Kinesis Monetary System recently launched gold-based stable coin can provide the trust that is needed in the industry.
Last week marked the 10th anniversary of the worst global financial crisis since the 1930s, which caused a lack of trust within the financial services sector.
Thomas Coughlin, CEO of Kinesis Monetary System, believes that this trust can be rebuilt using revolutionary blockchain technology.
The introduction of blockchain technology into the sector allows greater accountability through the form of digitised, shared and trackable data sets.
Kinesis Monetary Systems has tapped into this technology by creating secure and easily exchangeable, digital records of metal ownership on the blockchain.
About Kinesis Monetary System
The vision for Kinesis is to deliver an evolutionary step beyond any monetary system available today. This is achieved by basing the Kinesis currencies 1:1 on allocated physical gold and silver. Use is incentivised by attaching a unique yield system to the Kinesis currencies and distributing back the wealth generated according to proportionate currency holdings and velocity.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
